Bill Text: NY A02030 | 2021-2022 | General Assembly | Introduced
Bill Title: Relates to medication assisted treatment for substance abuse disorders; prohibits prior authorization.
Spectrum: Partisan Bill (Democrat 12-0)
Status: (Passed) 2021-12-22 - signed chap.720 [A02030 Detail]
Download: New_York-2021-A02030-Introduced.html
STATE OF NEW YORK ________________________________________________________________________ 2030 2021-2022 Regular Sessions IN ASSEMBLY January 14, 2021 ___________ Introduced by M. of A. L. ROSENTHAL, QUART, RICHARDSON, CARROLL, WEPRIN, SIMON, GOTTFRIED, HEVESI -- read once and referred to the Committee on Health AN ACT to amend the social services law and the public health law, in relation to medication for the treatment of substance use disorders The People of the State of New York, represented in Senate and Assem- bly, do enact as follows: 1 Section 1. Subdivision 2 of section 365-a of the social services law 2 is amended by adding a new paragraph (gg) to read as follows: 3 (gg) all buprenorphine products, methadone or long acting injectable 4 naltrexone for detoxification or maintenance treatment of a substance 5 use disorder prescribed according to generally accepted national profes- 6 sional guidelines for the treatment of a substance use disorder. Such 7 medication assisted treatment shall not be subject to any prior authori- 8 zation mandate. 9 § 2. Subdivision 26-b of section 364-j of the social services law, as 10 added by section 4 of part B of chapter 69 of the laws of 2016, is 11 amended to read as follows: 12 26-b. Managed care providers shall not require prior authorization for 13 [an initial or renewal prescription for buprenorphine or injectable14naltrexone for detoxification or maintenance treatment of opioid15addiction unless the prescription is for a non-preferred or non-formu-16lary form of the drug or as otherwise required by section 1927(k)(6) of17the Social Security Act] any buprenorphine products, methadone or long 18 acting injectable naltrexone for detoxification or maintenance treatment 19 of a substance use disorder prescribed according to generally accepted 20 national professional guidelines for the treatment of a substance use 21 disorder. 22 § 3. Subdivision 10 of section 273 of the public health law, as 23 amended by section 7 of part GG of chapter 56 of the laws of 2020, is 24 amended to read as follows: EXPLANATION--Matter in italics (underscored) is new; matter in brackets [] is old law to be omitted. LBD00371-02-1A. 2030 2 1 10. Prior authorization shall not be required for [an initial or2renewal prescription for buprenorphine or injectable naltrexone for3detoxification or maintenance treatment of opioid addiction unless the4prescription is for a non-preferred or non-formulary form of such drug5as otherwise required by section 1927(k)(6) of the Social Security Act.6Further, prior authorization shall not be required for] any buprenor- 7 phine products, methadone, [when used for opioid use disorder and admin-8istered or dispensed in an opioid treatment program] or long acting 9 injectable naltrexone for detoxification or maintenance treatment of a 10 substance use disorder prescribed according to generally accepted 11 national professional guidelines for the treatment of a substance use 12 disorder. 13 § 4. This act shall take effect on the ninetieth day after it shall 14 have become a law; provided, however, that the amendments to subdivision 15 26-b of section 364-j of the social services law made by section two of 16 this act shall not affect the repeal of such section, and shall be 17 deemed repealed therewith.